Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №10 (2024) > Efficacy of fremanezumab in patients with chronic migraine and concomitant depression

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression

A.Y. Timokhovich , A.V. Berdnikova , N.V. Latysheva

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Background. Migraine is a common chronic disorder that ranks third in the disability-adjusted life years among nervous system disorders. 
It is well known that migraine is strongly associated with the depression/anxiety disorders; there is overwhelming data suggesting common mechanisms underlying migraine and depression, including involvement of the neurotransmitter systems, such as calcitonin gene-related peptide (CGRP).
Aim. Efficacy of fremanezumab in patients with chronic migraine (CM) and concomitant depression.
Methods. A total of 48 patients aged 23–57 years with the established diagnosis of CM and depression took part in the study. Fremanezumab in a dose of 225 mg was administered monthly throughout 6 months. Clinical interviewing and headache diary assessment were performed every month, and the Hamilton Depression Inventory (Hamilton Depression Rating Scale) was filled during the first visit, on months 3 and 6.
Results. A significant decrease in the headache frequency with the steady increase of effect by month 3 of therapy and the effect persistence by month 6 of therapy is reported in patients with CM and depression. A significant decrease in the depression scores based on the Hamilton Depression Rating Scale is observed.
Conclusion. Fremanezumab can be used as one of the first-line drugs for treatment of patients with CM and concomitant depression.
Keywords. Migraine, monoclonal antibodies, chronic migraine, depression, fremanezumab, CGRP.

About the Author

A.Y. Timokhovich 1 , A.V. Berdnikova 2 , N.V. Latysheva 2

1 Clinic of Professor Kinzersky, Chelyabinsk, Russia

2 Alexander Vein Headache Clinic, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

References

1. Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023 Feb;19(2):109-117.
2. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Apr;23(4):344-381.
3. Ashina M, Katsarava Z, Do TP et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-1495.
4. Zhang Q, Shao A, Jiang Z, Tsai H, Liu W. The exploration of mechanisms of comorbidity between migraine and depression. J. Cell Mol. Med. 2019;23(7):4505-4513.
5. Satyanarayanan SK, Shih YH, Wen YR et al. miR-200a-3p modulates gene expression in comorbid pain and depression: Molecular implication for central sensitization. Brain Behav. Immun. 2019;82:230-238.
6. Wachowska K, Bliźniewska-Kowalska K, Sławek J et al. Common pathomechanism of migraine and depression. Psychiatria Polska. 2023;57(2):405-419.
7. Levin M, Silberstein SD, Gilbert R et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58(10):1689-1696. DOI: 10.1111/head.13439
8. Borkum JM. CGRP and brain functioning: Cautions for migraine treatment. Headache. 2019; 59(8): 1339–1357
9. Park S-H, Sim Y-B, Kim C-H et al. Role of α-CGRP in the regulation of neurotoxic responses induced by kainic acid in mice. Peptides. 2013;44:158-162.
10. Angelucci F, Ellenbroek BA, El Khoury A, Mathé AA. CGRP in a gene-environment interaction model for depression: Effects of antidepressant treatment. Acta Neuropsychiatr. 2019;31(2):93-99.
11. Troubat R, Barone P, Leman S et al. Neuroinflammation and depression: A review. Eur. J. Neurosci. 2021;53(1):151-171.
12. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Publishing, 2013.
14. Аджови 225 мг. Инструкция к лекарственному препарату на сайте Государственного реестра лекарственных средств. Доступ: (дата обращения – 19.04.2024).
Adjovi 225 mg. Instructions for the drug on the website of the State Register of Medicines. Access: https://grls.minzdrav.gov.ru (date of application – 04/19/2024) (in Russian).
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62.
16. Министерство здравоохранения Российской Федерации. Клинические рекомендации: Мигрень. Всероссийское общество неврологов, Межрегиональная общественная организация «Российское общество по изучению головной боли». 2021. URL: https://cr.minzdrav.gov.ru/schema/295_2 (дата обращения: 19.04. 2024)
The Ministry of Health of the Russian Federation. Clinical recommendations: Migraine. All-Russian Society of Neurologists, Interregional public organization «Russian Society for the Study of Headache». 2021. URL: https://cr.minzdrav.gov.ru/schema/295_2 (date of application: 04/19/2024) (in Russian).
17. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan;59(1):1-18.

For citation:Timokhovich A.Yu., Berdnikova A.V., Latysheva N.V. Efficacy of fremanezumab in patients with chronic migraine and concomitant depression. Clinical review for general practice. 2024; 5 (10): 113–117 (In Russ.). DOI: 10.47407/kr2024.5.10.00504


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru